Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | GABRR1 | P24046 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | RGS12 | O14924 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | GABRR2 | P28476 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | GNAI1 | P63096 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL29391283 | 0.98 | TSHR (0.96) | TSHRGABRR1BLMRGS12CYP3A4 | |
| SCHEMBL21564367 | 0.83 | TSHR (0.71) | TSHRGABRR1BLMRGS12CYP3A4 | |
| SCHEMBL8830889 | 0.79 | TSHR (0.66) | TSHRGABRR1BLMRGS12CYP3A4 | |
| SCHEMBL31590201 | 0.73 | — | — | |
| SCHEMBL31590156 | 0.67 | RGS12 (0.50) | TSHRGABRR1BLMRGS12CYP3A4 | |
| SCHEMBL15942710 | 0.67 | — | — | |
| SCHEMBL27720665 | 0.67 | TSHR (0.50) | TSHRGABRR1BLMRGS12CYP3A4 | |
| SCHEMBL3019512 | 0.63 | TSHR (0.60) | TSHRGABRR1BLMRGS12CYP3A4 | |
| SCHEMBL15319901 | 0.63 | TSHR (0.60) | TSHRGABRR1BLMRGS12CYP3A4 | |
| SCHEMBL9497437 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | claimed |
| US-11890266-B2 | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier | UNIVERSITY OF CANBERRA (AU) | 2024-02-06 | — | — | US | claimed |
| US-20220047529-A1 | METHODS OF INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2022-02-17 | — | — | US | claimed |
| EP-3849533-A1 | METHODS OF INHIBITION | University of Canberra (AU) | 2021-07-21 | — | — | EP | claimed |
| CN-112770734-A | Suppression method | 堪培拉大学 | 2021-05-07 | — | — | CN | claimed |
| US-20210077443-A1 | OPHTHALMIC COMPOSITIONS INCLUDING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIVERSITY OF CANBERRA (AU) | 2021-03-18 | — | — | US | claimed |
| US-10874629-B2 | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | UNIVERSITY OF CANBERRA (AU) | 2020-12-29 | — | — | US | claimed |
| WO-2020051648-A1 | METHODS OF INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2020-03-19 | — | — | WO | claimed |
| US-20190151270-A1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIVERSITY OF CANBERRA (AU) | 2019-05-23 | — | — | US | claimed |
| EP-3442516-A1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2019-02-20 | — | — | EP | claimed |
| WO-2017177262-A1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIVERSITY OF CANBERRA (AU) | 2017-10-19 | — | — | WO | claimed |
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | disclosed |
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024173903-A1 | AMANITA-MUSCARIA MUSHROOM EXTRACTS AND PRODUCTS, AND IMPROVED PROCESSES FOR PRODUCING EXTRACTS OF AMANITA-MUSCARIA MUSHROOMS AT KILOGRAM SCALE | PSYCHED WELLNESS LTD. (CA) | 2024-08-22 | — | — | WO | disclosed |
| CN-112770734-B | Inhibition method | 堪培拉大学 | 2024-08-20 | — | — | CN | disclosed |
| US-20030050232-A1 | Novel human proteins, polynucleotides encoding them and methods of using the same | CURAGEN CORPORATION | 2003-03-13 | — | — | US | disclosed |
| US-20020123612-A1 | Novel human proteins, polynucleotides encoding them and methods of using the same | CURAGEN CORPORATION | 2002-09-05 | — | — | US | disclosed |
| WO-2001079294-A2 | HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF USING THE SAME | CURAGEN CORPORATION (US) | 2001-10-25 | — | — | WO | disclosed |
| US-5627169-A | Selective antagonists for GABArho receptor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047529-A1 | METHODS OF INHIBITION | SLC6A3, DBH, SNCA | TSHR 1906/4885GABRR1 248/4885BLM 4564/4885 |
| US-11890266-B2 | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier | TTPA, TST, TXN2 | TSHR 1522/4885GABRR1 2709/4885BLM 3916/4885 |
| US-10874629-B2 | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | COMT, LRRK2, PARK7 | TSHR 3865/4885GABRR1 1175/4885BLM 1244/4885 |
| US-20190151270-A1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | COMT, LRRK2, PARK7 | TSHR 3865/4885GABRR1 1175/4885BLM 1244/4885 |
| US-20210077443-A1 | OPHTHALMIC COMPOSITIONS INCLUDING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | TTPA, TST, TXN2 | TSHR 1522/4885GABRR1 2709/4885BLM 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.